ProCE Banner Activity

From HIVR4P 2021, Welcome Results From 2 Trials of Long-Acting PrEP

Conference Coverage
Clinical Thought
Read my take on promising new data from HIVR4P 2021 on monthly oral islatravir and injectable cabotegravir as long-acting PrEP options.

Released: February 17, 2021

Expiration: February 16, 2022

Share

Faculty

Beatriz Grinsztejn

Beatriz Grinsztejn, MD, PhD

STI/AIDS Clinical Research Laboratory, Director
Instituto Nacional de Infectologia Evandro Chagas
FIOCRUZ
Rio de Janeiro, Brazil

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2021 HIV R4P

ProCE Banner

Faculty Disclosure

Primary Author

Beatriz Grinsztejn, MD, PhD

STI/AIDS Clinical Research Laboratory, Director
Instituto Nacional de Infectologia Evandro Chagas
FIOCRUZ
Rio de Janeiro, Brazil

Beatriz Grinsztejn, MD, PhD, has disclosed that she has received consulting fees from Janssen and Merck and funds for research support from Gilead Sciences and GSK/ViiV.